Early Access — free while we kick the tires
EdgarHawk

Reeve Emma

Director

Director
2 filings analyzed · 1 company · Latest 2025-10-31

Companies

Company Buys Sells Direction
PTC THERAPEUTICS, INC. PTCT 0 15 Net selling

Activity

October 2025
2025-10-31 PTC THERAPEUTICS, INC. PTCT
high
Sell
15,666 shares
$1,088,787
Significance 6/10

Director Reeve Emma sold 15,666 shares at $69.50 on 2025-10-30, reducing holdings by 70.2%; concurrent aggressive liquidation pattern at near 52-week high.

Director Reeve Emma executed 2 separate sales totaling 15,666 shares for $1,088,787.00 at $69.50 on 2025-10-30, liquidating 70.2% of her holdings and retaining only 6,666 shares post-transaction. The sales occurred at a price -0.3% from the 52-week high of $68.51, following a strong 30-day rally of +10.2% and 90-day appreciation of +31.0%. This follows a cluster of 5 prior sales by the same director at PTCT on 2025-10-03, suggesting a sustained liquidation pattern. The company is unprofitable (net income $-64,849,000.00 over the latest full fiscal year) with contracting revenue (annual growth -14.0% vs prior year), creating a backdrop of deteriorating fundamentals against which this substantial reduction in insider position becomes notable. The concentration of nearly 70% of holdings sold within days—and near peak valuation—warrants examination of whether material developments or management expectations are informing the director's exit strategy.

2025-10-07 PTC THERAPEUTICS, INC. PTCT
high
Sell
25,562 shares
$1,686,024
Significance 7/10

Director Emma Reeve sold 25,562 shares at $65.96 avg (9 sales totaling $1.7M), reducing stake 71.2% to 10,332 shares

Emma Reeve, a PTC Therapeutics director, executed 9 separate sales on 2025-10-03 totaling 25,562 shares for $1,686,023.74, reducing her post-transaction holding to 10,332 shares from 35,894 pre-transaction—a 71.2% reduction in her position. The sales were priced between $65.02 and $66.93 per share with a blended average of $65.96, and occurred in a company trading at $63.90 currently (within 2.2% of its 52-week high of $65.37). PTC Therapeutics faces significant headwinds: the company reported a $-64.8M net loss in its latest quarter despite $178.9M in revenue, and annual revenue declined 14.0% year-over-year, while remaining unprofitable for the full fiscal year. The substantial liquidation of a director's majority stake during near-52-week-high valuations, combined with persistent operational losses and contracting revenue, aligns with a period when the stock has appreciated significantly (up 31.1% over 90 days) following sustained losses.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access